-
GRUNENTHAL GMBH et al v. ALKEM LABORATORIES LIMITED DC CAFC
- 2:13-cv-07803
- D.N.J.
- Judge: Claire C. Cecchi
+1
- Filed: 12/23/2013
- Closed: 01/25/2016
- Latest Docket Entry: 09/17/2021
- PACER
- Docket updated daily
3
Plaintiffs
4
Defendants
1
Accused
Product
1
Patent-in-Suit
764
Days in
Litigation
-
GRUNENTHAL GMBH et al v. ALKEM LABORATORIES LIMITED DC CAFC
- 2:13-cv-07803
- D.N.J.
- Judge: Claire C. Cecchi
+1
- Filed: 12/23/2013
- Closed: 01/25/2016
- Latest Docket Entry: 09/17/2021
- PACER
- Docket updated daily
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
| Claim # | Claim Text | Outcome |
|---|---|---|
| 1 |
A method of treating polyneuropathic pain in a subject suffering therefrom, said method comprising administering to said subject an effective polyneuropathic pain inhibiting amount of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a
view more
|
Enforceable and Valid
Entry 203 Entry 179 |
| 2 |
A method according to claim 1, comprising administering a hydrochloride salt of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol.
|
Enforceable and Valid
Entry 203 Entry 179 |
| 3 |
A method according to claim 1, wherein said polyneuropathic pain is diabetic polyneuropathic pain.
|
Enforceable and Valid
Entry 203 Entry 179 |
| 6 |
A method of treating diabetic polyneuropathy in a subject suffering therefrom, said method comprising administering to said subject a pharmacologically effective amount of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically
view more
|
Enforceable and Valid
Entry 203 Entry 179 |
-
Infringement
Alkem Laboratories Limited
- 1 Detail
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| 15 mg200 mg20 mg250 mg tapentadol hydrochloride extended release tablets30 mg40 mg60 mg80 mgANDA No. 205016Generic 100 mgOxyContin 10 mg | US 8,536,130 B2 |
1, 2, 3, 6
|
Infringement
Entry 203Entry 179 |
